NCT06346938 The Clinical Significance of CT-based Biomarkers in the Classification and Prognosis of Bronchiectasis
| NCT ID | NCT06346938 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Condition | Bronchiectasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-03-30 |
| Primary Completion | 2027-03-26 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-03-30 with a primary completion date of 2027-03-26.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As the third major chronic airway disease in China, bronchiectasis has a wide range of patients. However, the involved sites, morphological features and airway obstruction of bronchiectasis are varied, and clinical heterogeneity is high, making prognosis and severity difficult to evaluate. CT plays an important role in the diagnosis and classification of ramadasis. Based on this, we analyzed the CT findings of patients with bronchiectasis and followed up patients with bronchiectasis to understand their disease progression and prognosis, so as to further analyze the role of CT biomarkers in the type and prognosis of bronchiectasis diseases.
Eligibility Criteria
Inclusion Criteria: * Age 18 years and above; * Can cooperate with CT scan; * Bronchiectasis confirmed by high-resolution computed tomography of the lungs; * Can provide written informed consent Exclusion Criteria: * Pulmonary surgery; * Patients with lung cancer, asthma and other respiratory diseases; * Tractive bronchiectasis caused by pulmonary fibrosis; * Patients with malignant tumors or serious dysfunction of the heart, brain, kidney and other important systems can not cooperate with the completion of this study； * Lack of important clinical information.
Contact & Investigator
xiaorong Wang
PRINCIPAL INVESTIGATOR
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Frequently Asked Questions
Who can join the NCT06346938 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Bronchiectasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06346938 currently recruiting?
Yes, NCT06346938 is actively recruiting participants. Contact the research team at rong-100@163.com for enrollment information.
Where is the NCT06346938 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT06346938 clinical trial?
NCT06346938 is sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The principal investigator is xiaorong Wang at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The trial plans to enroll 300 participants.